Vasoactive Intestinal Peptide
moderate riskAlso: VIP · VPAC1/VPAC2 agonist · Aviptadil
VIP (Vasoactive Intestinal Peptide) is a potent endogenous neuropeptide with anti-inflammatory, vasodilatory, and immunomodulatory properties. Aviptadil (inhaled VIP) received emergency authorization during COVID-19. Evidence for ARDS and pulmonary hypertension in Phase II trials.
Reported Benefits
Pulmonary arterial hypertension
Phase II RCT shows hemodynamic improvement and reduced pulmonary resistance.
COVID-19 / ARDS
Aviptadil EUA data: reduced progression to mechanical ventilation in COVID ARDS.
Anti-inflammatory (IBD/autoimmune)
Consistent preclinical anti-inflammatory effects; clinical trials ongoing.
Mechanism of Action
VPAC1/VPAC2 receptor agonist; increases cAMP; inhibits TNF-α, IL-6, IFN-γ; promotes Treg cells; bronchodilatory and vasodilatory effects in pulmonary vasculature.
Key Clinical Studies
Leuchte et al. (2008)
Phase II RCT · n=20
Improved hemodynamics and exercise tolerance in pulmonary hypertension
Aviptadil and COVID-19
During COVID-19, inhaled aviptadil (synthetic VIP) received Emergency Use Authorization based on early trial data showing reduced mechanical ventilation rates. This gave VIP one of the few human COVID efficacy data sets in the peptide space.
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Flushing
- •Hypotension
- •Tachycardia
- •GI cramping
Contraindications
- •Severe hypotension
- •Hypersensitivity
Drug Interactions
- •Antihypertensives
Primary Uses
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Vasoactive Intestinal Peptide?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →